header-9.jpg
Grants

The Microniche: A novel in vitro and in vivo prostate cancer model system

The overall aim of this project is to determine how androgen deprivation therapy (ADT) modifies bone marrow stromal cell signalling, how this influences the behaviour of authenticated prostate cancer primary cell lines in vitro, and how ADT and bone marrow stromal cell composition influence prostate cancer xenograft establishment in bone marrow and subsequent drug sensitivity.

Specifically, we aim to:

  1. Use the in vitro 3D microniche platform to characterise the precise impact of ADT on bone marrow stromal cell behaviour and paracrine signalling profile.

  2. Use the in vitro 3D microniche platform to characterise prostate cancer cell proliferation and drug sensitivity in response to complex ADT-associated changes in bone marrow paracrine signalling.

  3. Use the in vivo 3D microniche direct bone marrow injection platform to characterise the influence of bone marrow stromal cell composition and ADT-influenced bone marrow signalling on prostate cancer xenograft establishment in bone and drug sensitivity.

 

Investigators

Michael Doran APCRC-Q, IHBI, QUT, TRI
Ian Vela APCRC-Q, PAH, IHBI, QUT, TRI
Brian Tse APCRC-Q, IHBI, QUT, TRI
Pamela Russell APCRC-Q, IHBI, QUT, TRI

Duration

2016 - 2018

Funding

National Health and Medical Research Council $591 012